Cargando…
Safety, Tolerability, and Pharmacokinetics (PK) of Posaconazole (POS) Intravenous (IV) Solution and Oral Powder for Suspension in Children With Neutropenia
BACKGROUND: POS, a triazole antifungal approved for prophylaxis and treatment of adults with invasive fungal infections, is available as an IV solution and 2 oral formulations: an oral suspension and a tablet with improved bioavailability. A novel powder for oral suspension (PFS) has been developed...
Autores principales: | Groll, Andreas H, Abdel-Azim, Hisham, Lehrnbecher, Thomas, Steinbach, William, Murray, RoseAnn, Paschke, Amanda, Mangin, Eric, Winchell, Gregory A, Bruno, Christopher J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631567/ http://dx.doi.org/10.1093/ofid/ofx163.681 |
Ejemplares similares
-
1558. A Population Pharmacokinetic Model for Posaconazole Intravenous Solution and Oral Powder for Suspension Formulations in Pediatric Patients With Neutropenia
por: Winchell, Gregory A, et al.
Publicado: (2019) -
A non-randomized trial to assess the safety, tolerability, and pharmacokinetics of posaconazole oral suspension in immunocompromised children with neutropenia
por: Arrieta, Antonio C., et al.
Publicado: (2019) -
Therapeutic Drug Monitoring (TDM) of Suspension (SUS), Extended-Release (ER), and Intravenous (IV) Posaconazole (POS) at a Large Transplant Center
por: Haidar, Ghady, et al.
Publicado: (2017) -
Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia
por: Döring, M., et al.
Publicado: (2015) -
Implications for IV posaconazole dosing in the era of obesity
por: Wasmann, Roeland E, et al.
Publicado: (2020)